BioCentury | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
BioCentury | Oct 19, 2018
Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
BioCentury | Feb 6, 2018
Preclinical News

Wilson reports fatal primate toxicity with second AAV9 variant

Gene therapy pioneer James Wilson reported in Molecular Therapy a second instance of a non-human primate death in a pilot study testing high systemic dosing of a variant of adeno-associated viral vector 9, but not...
BioCentury | Jan 5, 2018
Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the expansion portion of a Phase IIa trial in 16 patients with relapsed or refractory acute myelogenous leukemia (AML) showing that BL-8040 as monotherapy for two days...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Cardiovascular

...MR-409) in preclinical testing to treat myocardial infarction (MI). Theratechnologies Inc., AOP Orphan Pharmaceuticals AG, BL&H Co. Ltd....
BioCentury | Aug 10, 2017
Clinical News

Genentech starts Phase Ib/II evaluating immunotherapy-based combos for pancreatic ductal adenocarcinoma

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) began an open-label, international Phase Ib/II trial to evaluate multiple immunotherapy-based combinations with PD-L1 inhibitor Tecentriq atezolizumab (MPDL3280A, RG7446) compared to chemotherapy with gemcitabine plus Abraxane nab-paclitaxel...
BioCentury | Feb 9, 2017
Clinical News

BL-8040: Ph II started

BioLineRx said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase II trial to evaluate subcutaneous 1.25 mg/kg BL-8040 plus 200 mg IV Keytruda pembrolizumab in about 15 patients. Patients will...
BioCentury | Oct 3, 2016
Company News

Ben-Gurion University, Hadassah Medical Organization, BioLineRx deal

The organization’s Hadasit Medical Research Services & Development Ltd. technology transfer arm and the university’s BGN Technologies technology transfer arm granted BioLineRx exclusive, worldwide rights to BL-1220 , a preclinical liver fibrosis and non-alcoholic steatohepatitis (NASH)...
BioCentury | Sep 26, 2016
Clinical News

BL-8040: Phase IIa started

BioLineRx began the open-label, international Phase IIa COMBAT trial to evaluate 1.25 mg/kg subcutaneous BL-8040 with or without Keytruda pembrolizumab in up to 30 patients. In January, BioLineRx partnered with Merck & Co. Inc. (NYSE:MRK,...
BioCentury | Sep 12, 2016
Company News

BioLineRx, Genentech, Roche deal

BioLineRx and Roche’s Genentech unit partnered to conduct Phase Ib trials evaluating BioLineRx’s BL-8040 plus Genentech’s Tecentriq atezolizumab. Genentech will conduct several trials in solid cancers, and BioLineRx will conduct a single trial in acute...
Items per page:
1 - 10 of 206
BioCentury | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
BioCentury | Oct 19, 2018
Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
BioCentury | Feb 6, 2018
Preclinical News

Wilson reports fatal primate toxicity with second AAV9 variant

Gene therapy pioneer James Wilson reported in Molecular Therapy a second instance of a non-human primate death in a pilot study testing high systemic dosing of a variant of adeno-associated viral vector 9, but not...
BioCentury | Jan 5, 2018
Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the expansion portion of a Phase IIa trial in 16 patients with relapsed or refractory acute myelogenous leukemia (AML) showing that BL-8040 as monotherapy for two days...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Cardiovascular

...MR-409) in preclinical testing to treat myocardial infarction (MI). Theratechnologies Inc., AOP Orphan Pharmaceuticals AG, BL&H Co. Ltd....
BioCentury | Aug 10, 2017
Clinical News

Genentech starts Phase Ib/II evaluating immunotherapy-based combos for pancreatic ductal adenocarcinoma

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) began an open-label, international Phase Ib/II trial to evaluate multiple immunotherapy-based combinations with PD-L1 inhibitor Tecentriq atezolizumab (MPDL3280A, RG7446) compared to chemotherapy with gemcitabine plus Abraxane nab-paclitaxel...
BioCentury | Feb 9, 2017
Clinical News

BL-8040: Ph II started

BioLineRx said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase II trial to evaluate subcutaneous 1.25 mg/kg BL-8040 plus 200 mg IV Keytruda pembrolizumab in about 15 patients. Patients will...
BioCentury | Oct 3, 2016
Company News

Ben-Gurion University, Hadassah Medical Organization, BioLineRx deal

The organization’s Hadasit Medical Research Services & Development Ltd. technology transfer arm and the university’s BGN Technologies technology transfer arm granted BioLineRx exclusive, worldwide rights to BL-1220 , a preclinical liver fibrosis and non-alcoholic steatohepatitis (NASH)...
BioCentury | Sep 26, 2016
Clinical News

BL-8040: Phase IIa started

BioLineRx began the open-label, international Phase IIa COMBAT trial to evaluate 1.25 mg/kg subcutaneous BL-8040 with or without Keytruda pembrolizumab in up to 30 patients. In January, BioLineRx partnered with Merck & Co. Inc. (NYSE:MRK,...
BioCentury | Sep 12, 2016
Company News

BioLineRx, Genentech, Roche deal

BioLineRx and Roche’s Genentech unit partnered to conduct Phase Ib trials evaluating BioLineRx’s BL-8040 plus Genentech’s Tecentriq atezolizumab. Genentech will conduct several trials in solid cancers, and BioLineRx will conduct a single trial in acute...
Items per page:
1 - 10 of 206